News Overview


Sina Kohlbrenner

SOTIO has been building a diverse biotechnology portfolio through own R&D, partnering and investments since 2010. It’s focusing on immuno-oncology and developing innovative methods of the treatment of cancer. SOTIO is conducting multiple Phase I to III clinical trials and projects in preclinical stage. The company has facilities in Europe, the US, China and Russia.

You may also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish.